Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024, at 8:55 a.m. PT (11:55 a.m. ET).

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD). Acumen's scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer's disease patients. For more information, visit www.acumenpharm.com .

Investors:
Alex Braun
abraun@acumenpharm.com

Media:
AcumenPR@westwicke.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABOS:US
The Conversation (0)

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

  • Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in May 2024

  • Initiation of a Phase 1 study to support a subcutaneous dosing option of sabirnetug expected in mid-2024

  • Cash, cash equivalents and marketable securities of $296.6 million as of Mar. 31, 2024, expected to support current clinical and operational activities into the first half of 2027

  • Company to host conference call and webcast today at 8:00 a.m. ET

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2024 and provided a business update.

"In the first quarter, our team remained laser-focused on the initiation of ALTITUDE-AD, our Phase 2 study investigating the efficacy and safety of sabirnetug for the treatment of early AD. We announced the first patient dosed in this study just last week. We are encouraged by the level of investigator interest in the potential of sabirnetug to offer a best-in-class therapeutic profile for patients, which is a testament to our strong Phase 1 data package and the relationships our team has built with clinical sites," Daniel O'Connell, Chief Executive Officer of Acumen. "We continue to expect to initiate a Phase 1 study with a subcutaneous form of sabirnetug in mid-2024 in an effort to extend the product profile and offer administration optionality for patients. We remain committed to delivering on our strategic priority to advance the clinical development of sabirnetug efficiently and thoughtfully."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the H.C. Wainwright 2 nd Annual BioConnect Conference on Monday, May 20, 2024, at 12:30 p.m. ET.

The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug in Early Alzheimer's Disease

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today announced that the first patient has been dosed with sabirnetug (ACU193) in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD.

"Today marks a significant milestone for Acumen and the Alzheimer's community as we begin the Phase 2 trial of sabirnetug," said Daniel O'Connell, Chief Executive Officer of Acumen. "Sabirnetug is at the forefront of the next generation of Alzheimer's therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug's therapeutic potential and a strong start to the trial."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2024 financial results on Tuesday, May 14, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link . After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Vertex Minerals Limited  Underground Production Commences at the Reward Gold Mine Project

Vertex Minerals Limited Underground Production Commences at the Reward Gold Mine Project

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) (OTCMKTS:VTXXF) commences underground production at the Reward Gold Mine, moving to high grade gold production.

Operational Milestones

- First blasting of gold producing ore on the Lady Belmore Reef was undertaken over the weekend.

- The material will start complementing the low-grade gold stockpile feed to the Gravity Processing Plant, until all mining fronts are enabled.

- In forthcoming weeks, VTX remains firmly on track to commence processing of high-grade stope ore from the underground mine.

- The Reward Underground 11kva to 1000v Transformer Substation is installed and powered up. Cabling to the Primary Fan is completed.

- Access Drives to the two Starter Stopes are being cleaned, ready for the Production Rig to commence drilling the High-Grade Stopes.

- Decline 3 developed on the Mica Vein is fully dewatered, ready to be flatback mined for providing further gold feed to the Gravity Plant.

- Vertex aims to have developed at least 4 mining fronts and maintain continuous feed to the plant, which will involve various mining methods.

- Mining the Reward Gold Mine - Resource 225kozs at 16.7g/t

As previously announced, the startup mine schedule includes mining 2,075 tonnes at 17.8 g/t Au from a developed airleg stope block. The planned stope width is the same as the interpretation of the mineralisation. Refer to VTX ASX announcement 4th June 2025

Given the stope will take some time to extract, additionally, the Vertex Geology and Mining Team have brought forward a very high-grade long hole stope to commence mining in August 2025. The high-grade long hole stope isto be mined with a long hole stope method, using the Epiroc Production Rig.

*To view photographs, please visit:
https://abnnewswire.net/lnk/2U10401V



About Vertex Minerals Limited:

Vertex Minerals Limited (ASX:VTX,OTC:VTXXF) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Prismo Metals Announces Closing of Oversubscribed Private Placement

Prismo Metals Announces Closing of Oversubscribed Private Placement

(TheNewswire)

Vancouver, British Columbia, August 8th, 2025 TheNewswire Prismo Metals Inc. (" Prismo " or the " Company ") (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to announce that further to its news releases dated July 3, 2025, July 18, 2025 and July 31, 2025, the Company has proceeded with an upsized closing of its previously announced non-brokered private placement (the "Private Placement" ) of units of the Company (" Units ") at an issue price of $0.06 per Unit (the " Third Closing "). The closing was increased from 6,000,000 Units to the issuance of 6,425,000 Units for gross proceeds of $385,500.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing

OTCQB Venture Virtual Investor Conference: Presentations Now Available for Online Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the OTCQB Venture Virtual Investor Conference, held August 7 th are now available for online viewing.

REGISTER AND VIEW PRESENTATIONS HERE

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Seismic Equipment Arrives For Enercam Resources' Oil & Gas Block VIII, Cambodia

Seismic Equipment Arrives For Enercam Resources' Oil & Gas Block VIII, Cambodia

(TheNewswire)

GRANDE PRAIRIE, ALBERTA - August 6, 2025 TheNewswire - Angkor Resources Corp. (TSXV: ANK,OTC:ANKOF) ("ANGKOR" OR "THE COMPANY") announces its subsidiary, EnerCam Resources Co. Ltd. (Cambodia) ("EnerCam") has landed seismic equipment from seismic contractor GeneSeis Company Limited Thailand ("GeneSeis") to commence Cambodia's first onshore EnviroVibe oil and gas seismic for Block VIII ("Project").

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Forte Minerals Engages Strategic Advisors, Expands Capital Markets Team, and Launches AI-Powered Investor Tool

Forte Minerals Engages Strategic Advisors, Expands Capital Markets Team, and Launches AI-Powered Investor Tool

Forte Minerals Corp . (" Forte " or the " Company ") ( CSE: CUAU ) ( OTCQB: FOMNF ) ( Frankfurt: 2OA ) is pleased to announce the expansion of its capital markets capabilities with three strategic initiatives:

  • The engagement of Mills Dunlop Capital Partners as M&A and strategic advisors;
  • The appointment of Port Guichon Strategic Advisory, as Investor Relations and Capital Markets Specialist;
  • And the launch of a new AI-powered investor platform via Versance.ai.

These additions support Forte's commitment to investor engagement, capital markets excellence, and digital transparency.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Questcorp Mining and Riverside Resources Announce Commencement of Maiden Drilling Program at the La Union Gold & Silver Project in Mexico

Questcorp Mining and Riverside Resources Announce Commencement of Maiden Drilling Program at the La Union Gold & Silver Project in Mexico

Questcorp Mining Inc. (CSE: QQQ,OTC:QQCMF) (OTCQB: QQCMF) (FSE: D910) (the "Company" or "Questcorp") is pleased to announce that drilling has commenced on its La Union Project in northwest Sonora, Mexico. This work is being carried out by property vendor and operator Riverside Resources Inc. (TSXV: RRI).

Highlights

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×